Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06153069 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Asymptomatic TB With Innovative Modified Short-course Regimens

Study acronym: SWIFT
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Active, Not Recruiting to Recruitingv3 Show 13 more changesShow less
    • Primary completion date: Oct 2025 to Nov 2027
    • Start date: Nov 1, 2023 to Nov 21, 2025
    • Primary endpoint revised
    • Enrollment target: 556 to 426
    • Study sites: 2 to 5
    • Study completion date: Nov 2027 to Nov 2028
    • Interventions: Short-course regimen (Drug), Standard regimen (Drug) to Four-month regimen (Drug), Standard regimen (Drug), Three-month regimen (Drug)
    • Eligibility criteria shortened, about 23 words
    • Secondary endpoints: 5 to 9
    • Study description expanded, about 19 words
    • Study title revised
    • Study arms: 2 to 3
    • Collaborators expanded, about 3 words
  2. Secondary endpoints: details revised at 1 of 5 entriesv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifapentine and moxifloxacin.
Trial Details
NCT Number NCT06153069
Lead Sponsor Huashan Hospital
Collaborators: University of Toronto
Conditions
(from sponsor)		 Tuberculosis
Related terms Tuberculosis
Enrollment 426 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov